Alcon Loses Patent Ruling on Padagis Copy of Simbrinza Eye Drops

Alcon Inc. failed to block Padagis Israel Pharmaceuticals Ltd. from selling a generic version of its Simbrinza eye drops after a Delaware federal judge ruled the copy doesn’t infringe its patent.

Padagis’ generic of the drug—which treats elevated pressure inside the eye—doesn’t infringe US Patent No. 9,421,265, which covers Simbrinza’s pharmaceutical composition, Judge William C. Bryson wrote in a Feb. 5 opinion unsealed Tuesday in the US District Court for the District of Delaware. He also issued a final judgment Tuesday.

• Bryson, sitting by designation from the US Court of Appeals for the Federal Circuit, upheld the patent’s validity. ...